IN THE CLAIMS

Please amend the claims as follows:

Claim 1 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof at least one phosphinic pseudopeptide derivative comprising the amino acid sequence of formula (I) below:



(I)

wherein,

- R_2 and R_3, which are identical or different, represent the side chain of a natural or unnatural amino acid, the sequence:



also possibly forming the Pro (proline) residue, and

- R_5 represents a hydrogen atom, a pharmacologically acceptable counterion, or a group that forms an *in vivo* hydrolysable phosphinic ester.

Claim 2 (Previously Presented): A method for selectively inhibiting the C-terminal site of angiotensin I converting enzyme comprising administering to a patient in need thereof a phosphinic pseudopeptide derivative corresponding to formula (II) below: